Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amg-900. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 4/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 3/20 | 1.00 |
| ▸ | AURKC known ✓ | Q9UQB9 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | CLK3 | P49761 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | TOP2B | Q02880 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amg-900 SCHEMBL29479191 | 1.00 | AURKA (1.00) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| Amg-900 SCHEMBL29351414 | 1.00 | AURKA (1.00) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581178 | 0.92 | AURKB (0.84) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580354 | 0.91 | AURKA (0.84) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581542 | 0.90 | AURKA (0.82) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL581159 | 0.90 | AURKB (0.81) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL16290183 | 0.90 | AURKA (0.81) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580342 | 0.89 | AURKA (0.80) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580667 | 0.88 | AURKA (0.78) | AURKAAURKBULK1RPS6KA5RPS6KA4 | |
| SCHEMBL580529 | 0.88 | AURKA (0.78) | AURKAAURKBULK1RPS6KA5RPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-09-23 | — | — | US | claimed |
| US-11730750-B2 | Drugs for GRP78 cell surface translocation and Par-4 secretion | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-08-22 | — | — | US | claimed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| US-20200181284-A1 | EPIGENETIC INHIBITORS FOR SENSITIZING HEMATOLOGIC OR OTHER MALIGNANCIES TO GLUCOCORTICOID THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-06-11 | — | — | US | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| EP-2818170-B1 | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | AMGEN INC (US) | 2018-12-05 | — | — | EP | claimed |
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | claimed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | claimed |
| EP-2475368-A1 | N-4 ( - ( ( 3- ( 2 -AMINO-4 PYRIMIDINYL) -2 -PYRIDINYL) OXY) PHENYL) -4- (4-METHYL-2-THIENYL) -1-PHTHALAZINAMINE FOR USE IN THE TREATMENT OF ANTIMITOTIC AGENT RESISTANT CANCER | Amgen, Inc (US) | 2012-07-18 | — | — | EP | claimed |
| US-20120028917-A1 | Use Of N-(4-((3-(2-Amino-4-Pyrimidinyl)-2-Pyridinyl)Oxy)Phenyl)-4-(4-Methyl-2-Thienyl)-1-Phthalazinamine In The Treatment Of Antimitotic Agent Resistant Cancer | AMGEN INC. (US) | 2012-02-02 | — | — | US | claimed |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2011-10-27 | — | — | US | claimed |
| US-8022221-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-09-20 | — | — | US | claimed |
| WO-2011031842-A1 | N-4 ( - ( ( 3- ( 2 -AMINO-4 PYRIMIDINYL) -2 -PYRIDINYL) OXY) PHENYL) -4- (4-METHYL-2-THIENYL) -1-PHTHALAZINAMINE FOR USE IN THE TREATMENT OF ANTIMITOTIC AGENT RESISTANT CANCER | AMGEN INC. (US) | 2011-03-17 | — | — | WO | claimed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | claimed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | claimed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | claimed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181284-A1 | EPIGENETIC INHIBITORS FOR SENSITIZING HEMATOLOGIC OR OTHER MALIGNANCIES TO GLUCOCORTICOID THERAPY | NR3C1, EZH2, MECP2 | AURKA 1971/4885AURKB 707/4885AURKC 1180/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | AURKA 2/4885AURKB 4/4885AURKC 1/4885 |
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | MCL1, BAD, ACIN1 | AURKA 2005/4885AURKB 733/4885AURKC 776/4885 |
| US-20120028917-A1 | Use Of N-(4-((3-(2-Amino-4-Pyrimidinyl)-2-Pyridinyl)Oxy)Phenyl)-4-(4-Methyl-2-Thienyl)-1-Phthalazinamine In The Treatment Of Antimitotic Agent Resistant Cancer | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885AURKC 2/4885 |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885AURKC 1/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885AURKC 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.